Aclaris Therapeutics FY Conference Summary Company Overview - Aclaris Therapeutics is a clinical-stage biotech company focused on discovering and developing therapeutics for inflammatory and immunological conditions. The leadership team has extensive experience in drug development from companies like MedImmune, AZ, Centocor, J&J, GSK, and Pfizer [2][4]. Clinical Pipeline - Aclaris has three clinical-stage programs, including: - **Bosakitug**: An anti-TSLP monoclonal antibody completing a Phase II study in atopic dermatitis (AD) in 2026 [2][4]. - **ATI-052**: A bispecific antibody targeting TSLP and IL-4, with ongoing Phase I studies [3][12]. - **ATI-2138**: A potent ITK inhibitor combined with JAK3, with plans for further clinical trials [3][48]. Key Data and Results - **Bosakitug**: - Demonstrated a 90% EASI-75 response in a proof-of-concept study and over 80% responders in IJ01 [6]. - Retention time of 400 hours, significantly longer than competitors like tezepelumab [5][6]. - Expected to show top-line results by the end of 2026 [10]. - **ATI-052**: - Phase I study showed a 26-day half-life, three times longer than dupilumab [18]. - Demonstrated four times more potency than the combination of Tezspire and dupilumab in inhibiting TSLP IL-4-activated PBMC populations [19]. - Safety profile was favorable, with no significant adverse events reported [20]. - **ATI-2138**: - Focused on indications with less competition from existing JAK inhibitors, such as alopecia [46][47]. - Preclinical data showed promising results in severe models of alopecia [47]. Future Plans and Expectations - Aclaris plans to submit an IND for ATI-9494 by the end of the year [48]. - The company is optimistic about the potential of its programs, with data expected in the second half of the year for both bosakitug and ATI-052 [34][38]. - The company aims to explore additional indications for its therapies based on the outcomes of ongoing studies [11][42]. Market Position and Competitive Landscape - Aclaris believes its therapies could offer advantages over existing treatments like dupilumab, particularly in dosing frequency and targeting broader patient populations [38][39]. - The company is positioning itself to capitalize on the growing market for treatments in atopic dermatitis and asthma, with a focus on both T2 high and T2 low patient populations [26][39]. Conclusion - Aclaris Therapeutics is poised for significant developments in 2026, with multiple clinical trials underway and promising data expected. The company is strategically targeting unmet medical needs in the inflammatory and immunological space, with a strong emphasis on safety and efficacy in its drug development efforts [4][51].

Soquelitinib Overview - Soquelitinib is a first-in-class immune modulator with broad potential in cancer and immune diseases, targeting ITK [4, 5] - It has a novel mechanism of action with opportunities in oncology and immune diseases [5] - The drug has demonstrated a convenient oral dosing and attractive safety/tolerability profile in over 100 patients [5] - Corvus has strong IP protection with issued composition patents extending to November 2037 [5] Clinical Trials and Data - A randomized Phase 3 trial in PTCL is enrolling, with the potential for the first fully FDA-approved drug for PTCL [23, 24] - Phase 1 study in atopic dermatitis (AD) showed a significant reduction in EASI score at 28 days of treatment [68] - In the AD study, the 200 mg BID dose showed earlier and deeper responses, along with greater reductions in itch [68] - In AD Cohorts 1 and 2 (N=24), the mean EASI change was a 54.6% reduction, while in Cohort 3 (N=12), it was a 64.8% reduction, compared to a 34.4% reduction in the combined placebo group (N=12) [42] - In AD Cohort 3, 50% of patients with baseline PP-NRS ≥4 experienced a ≥ 4-point decrease in PP-NRS at Day 28 [53] Market and Future Development - The atopic dermatitis (AD) market is projected to reach $28 billion by 2030 [34] - Angel Pharma initiated a Phase 1b/2 trial in China for atopic dermatitis in Q4 2025 [59, 62] - Corvus anticipates data from the atopic dermatitis Phase 1 extension cohort 4 in January 2026 and plans to initiate a Phase 2 trial in early Q1 2026 [58, 69]

Company Overview and Strategy - Aclaris is developing therapeutic franchises to address gaps in important Immune and Inflammatory (I&I) diseases, focusing on patient-driven innovation [1, 8] - The company anticipates having three clinical programs in 2025 and four in 2026, with 2026 being an important year for potential inflection points [11] - Aclaris expects its cash runway to extend into the second half of 2028, supporting its preclinical and clinical development plans [11, 14] Pipeline and Programs - Aclaris's pipeline includes Bosakitug (ATI-045), a monoclonal antibody targeting TSLP, ATI-052, a bispecific antibody targeting both TSLP and IL-4Rα, and ATI-2138, an oral inhibitor of ITK/JAK3 [14] - ATI-2138's Phase 2a open-label trial in Atopic Dermatitis (AD) achieved primary and key secondary endpoints, validating ITK as a therapeutic target; at week 12, 63% of patients experienced a ≥4-point improvement in worst itch [14, 103] - Bosakitug is currently in a two-arm placebo-controlled Phase 2 trial, while ATI-052 is in a Phase 1a/1b SAD MAD program with ongoing dosing [14] - The company is developing next-generation ITK selective inhibitors and bispecific antibodies, with potential for IND submissions starting in 2026 [14, 61] Market Opportunity and Technology - The total addressable market for select Th1, Th2, and Th17-mediated diseases is projected to be in the range of $0 to $70 billion globally from 2028-2034 [16] - Aclaris is leveraging its KINect® Technology Platform to target approximately 60% of the Kinome, with the annual sales of kinase drugs in 2024 at $62.8 billion and a market opportunity of $88.6 billion in 2029 [28, 30] - The global healthcare spending in autoimmune diseases in 2024 was $215 billion, with a global AI disease therapeutics market opportunity of $396 billion by 2030 [38] - Multi-specific antibodies had annual sales of $12.6 billion in 2024, highlighting an opportunity for best-in-class multi-specific antibodies for autoimmune and inflammatory diseases [38]

Soquelitinib作用机制和潜力 - Soquelitinib 是一种 First-in-Class 的免疫调节剂，在癌症和免疫疾病领域具有广泛的机会[4] - Soquelitinib 通过阻断 ITK 信号通路，能够调节 Th1/Th2/Th17 细胞的平衡，从而影响多种炎症细胞因子的产生[11, 29] - ITK 抑制剂具有广阔的治疗潜力，包括肿瘤免疫治疗、免疫疾病、肺部炎症、胃肠道疾病、纤维化疾病和皮肤病等[7] - Corvus 团队的领导成员曾参与 rituximab 和 ibrutinib 的开发[5] Soquelitinib 在 Atopic Dermatitis (AD) 临床试验中的结果 - 在 AD 的 Phase 1 临床试验中，Soquelitinib 在 Cohorts 1 和 2 中显示出 54.6% 的 EASI 平均降低[42] - Cohort 3 的 EASI 平均降低为 64.8%[42] - Cohort 3 中，50% 的患者在第 28 天实现了 PP-NRS 评分至少降低 4 分，表明瘙痒症状得到显著改善[53] - 在接受 Soquelitinib 治疗的患者中，75% 在 EASI 50 中有所改善，83% 在 EASI 50 中有所改善[42] - 29% 的患者在 EASI 75 中有所改善，50% 的患者在 EASI 75 中有所改善[42] - 4% 的患者在 EASI 90 中有所改善，8% 的患者在 EASI 90 中有所改善[42] - 21% 的患者 IGA 0 或 1 中有所改善，25% 的患者 IGA 0 或 1 中有所改善[42] Soquelitinib 的安全性 - 在 Cohorts 1、2 和 3 中，Soquelitinib 表现出良好的安全性和耐受性，未发生严重不良事件[49] - 38.9% 的 Soquelitinib 治疗患者出现不良反应，而安慰剂组为 25%[49] AD 市场机会 - G7 国家有大约 30 million 的 AD 患者，其中约 3 million 为中重度患者，但只有 10% 接受了先进疗法治疗[34] - AD 市场预计到 2030 年将达到 280 亿美元[34]